Francesca Valdora1, Nehmat Houssami2, Federica Rossi1, Massimo Calabrese3, Alberto Stefano Tagliafico4,5. 1. Department of Health Sciences, University of Genova, Via L.B. Alberti 2, 16132, Genoa, Italy. 2. Sydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 3. Ospedale Policlinico San Martino IST, Genoa, Italy. 4. Department of Health Sciences, University of Genova, Via L.B. Alberti 2, 16132, Genoa, Italy. alberto.tagliafico@unige.it. 5. Ospedale Policlinico San Martino IST, Genoa, Italy. alberto.tagliafico@unige.it.
Abstract
PURPOSE: To perform a rapid review of the recent literature on radiomics and breast cancer (BC). METHODS: A rapid review, a streamlined approach to systematically identify and summarize emerging studies was done (updated 27 September 2017). Clinical studies eligible for inclusion were those that evaluated BC using a radiomics approach and provided data on BC diagnosis (detection or characterization) or BC prognosis (response to therapy, morbidity, mortality), or provided data on technical challenges (software application: open source, repeatability of results). Descriptive statistics, results, and radiomics quality score (RQS) are presented. RESULTS: N = 17 retrospective studies, all published after 2015, provided BC-related radiomics data on 3928 patients evaluated with a radiomics approach. Most studies were done for diagnosis and/or characterization (65%, 11/17) or to aid in prognosis (41%, 7/17). The mean number of radiomics features considered was 100. Mean RQS score was 11.88 ± 5.8 (maximum value 36). The RQS criteria related to validation, gold standard, potential clinical utility, cost analysis, and open science data had the lowest scores. The majority of studies n = 16/17 (94%) provided correlation with histological outcomes and staging variables or biomarkers. Only 4/17 (23%) studies provided evidence of correlation with genomic data. Magnetic resonance imaging (MRI) was used in most studies n = 14/17 (82%); however, ultrasound (US), mammography, or positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F FDG PET/CT) was also used. Much heterogeneity was found for software usage. CONCLUSIONS: The study of radiomics in BC patients is a new and emerging translational research topic. Radiomics in BC is frequently done to potentially improve diagnosis and characterization, mostly using MRI. Substantial quality limitations were found; high-quality prospective and reproducible studies are needed to further potential application.
PURPOSE: To perform a rapid review of the recent literature on radiomics and breast cancer (BC). METHODS: A rapid review, a streamlined approach to systematically identify and summarize emerging studies was done (updated 27 September 2017). Clinical studies eligible for inclusion were those that evaluated BC using a radiomics approach and provided data on BC diagnosis (detection or characterization) or BC prognosis (response to therapy, morbidity, mortality), or provided data on technical challenges (software application: open source, repeatability of results). Descriptive statistics, results, and radiomics quality score (RQS) are presented. RESULTS: N = 17 retrospective studies, all published after 2015, provided BC-related radiomics data on 3928 patients evaluated with a radiomics approach. Most studies were done for diagnosis and/or characterization (65%, 11/17) or to aid in prognosis (41%, 7/17). The mean number of radiomics features considered was 100. Mean RQS score was 11.88 ± 5.8 (maximum value 36). The RQS criteria related to validation, gold standard, potential clinical utility, cost analysis, and open science data had the lowest scores. The majority of studies n = 16/17 (94%) provided correlation with histological outcomes and staging variables or biomarkers. Only 4/17 (23%) studies provided evidence of correlation with genomic data. Magnetic resonance imaging (MRI) was used in most studies n = 14/17 (82%); however, ultrasound (US), mammography, or positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F FDG PET/CT) was also used. Much heterogeneity was found for software usage. CONCLUSIONS: The study of radiomics in BC patients is a new and emerging translational research topic. Radiomics in BC is frequently done to potentially improve diagnosis and characterization, mostly using MRI. Substantial quality limitations were found; high-quality prospective and reproducible studies are needed to further potential application.
Entities:
Keywords:
Breast cancer; Characterization; Diagnosis; Magnetic resonance imaging; Prognosis; Radiomics
Authors: Karen Drukker; Maryellen L Giger; Bonnie N Joe; Karla Kerlikowske; Heather Greenwood; Jennifer S Drukteinis; Bethany Niell; Bo Fan; Serghei Malkov; Jesus Avila; Leila Kazemi; John Shepherd Journal: Radiology Date: 2018-12-11 Impact factor: 11.105